Genentech's anti-cancer drug Avastin (bevacizumab), when combined with standard chemotherapy, was proven to slow the progression of breast cancer in a new clinical trial conducted by Roche.

The study includes patients with metastatic breast cancer who never underwent prior treatment. Results revealed that patients who received Avastin in combination with chemotherapy had a longer time period before their cancer progressed as compared to patients who simply had chemotherapy

A study has showed that Britain lags behind other western countries when it comes to treatment of cancer. The country has one of the worst records over access to the latest cancer-fighting drugs and researchers have ranked it lowest for its "slow and low" uptake of drugs.

After analyzing sales of 67 treatments in 25 countries, the Swedish report said that other countries that make it to the list of worst cancer treatment include New Zealand, Poland, the Czech Republic and South Africa